Experimental treatment of neuroblastoma using [131I]meta- iodobenzylguanidine and topotecan in combination

British Journal of Radiology

Volumn 81, Issue SPECIAL ISSUE, 2008, Pages

  McCluskey, A G ^a   Boyd, M ^a   Pimlott, S L ^b   Babich, J W ^c   Gaze, M N ^d   Mairs, R J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c Clinical Research   (United States)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; NORADRENALIN TRANSPORTER; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL KILLING; CLONOGENESIS; CLONOGENIC ASSAY; COMET ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA REPAIR; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; TRANSGENE; TUMOR XENOGRAFT;

3-IODOBENZYLGUANIDINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA FRAGMENTATION; GLIOMA; MICE; MICE, NUDE; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOPHARMACEUTICALS; TOPOTECAN; TREATMENT OUTCOME;

EID: 49049090026     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/27723093     Document Type: Conference Paper

References (38)

1. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26:539-46.
2. 131I-meta-iodo-benzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer 1994;70:97-101.
3. Garaventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, De Bernardi B, et al. Treatment of advanced neuroblastoma with I-131 meta- Iodobenzylguanide. Cancer 1991;67:922-8.
4. Voute PA, Hoefnagel CA, de Kraker J, Valdes Olmos R, Bakker DJ, van de Kleij AJ. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC, editors. Advances in Neuroblastoma Research (3rd edn), Wiley-Liss, New York, 1991; 439-45.
5. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.
6. 131I]MIBG) in combination with other agents. Eur J Cancer 1999;8:1171-4.
7. Vassal G, Pondarré C, Capelli C, Terrier-Lacombe MJ, Boland I, Morizet J, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 1997;33:2011-15.
8. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumours: a Pediatric Oncology Group phase II study. J Ped Hematol Oncol 1998;20:315-18.
9. Miyamoto S, Huang TT, Wuerzberger-Davis S, Bornmann WG, Pink JJ, Tagliarino C, et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann NY Acad Sci 2000;922:274-92.
10. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett 2005;228:221-7.
11. 131I]meta-iodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929-37.
12. Dubois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-60.
13. Kramer K, Kushner BH, Cheung N-KV. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 2003;25:601-5.
14. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
15. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I - targeting drugs as radiosensitizers. Oncology 1999;13:39-46.
16. Hall EJ, editor. Radiosensitivity and cell age in the mitotic cycle. In: Radiobiology for the radiologist (4th edition). Philadelphia, PA: JB Lippincott company, 1994:91-105.
17. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumour cells by β-lapachone, an activator of topoisomerase I. Cancer Res 1989;49:605-12.
18. Boothman DA, Pardee AB. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc Natl Acad Sci U S A 1989;86:4963-7.
19. Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S, Owens JK. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 1992;24:939-48.
20. Cortes F, Pastor N. Ionizing radiation damage repair: a role for topoisomerases? Mutagenesis 2001;16:365-8.
21. Thielmann HW, Popanda O, Staab H-J. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and Xeroderma pigmentosum fibroblasts after irradiation with UV light and γ-rays or treatment with topotecan. J Clin Res Oncol 1999;125:193-208.
22. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde? Pathol Oncol Res 1999;5:171-8.
23. Beidler JL, Roffler-Tarlov S, Schwachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751-7.
24. 131I]meta- iodobenzylguanidine. GeneTher 1999;6:1147-52.
25. 123I]MIBG. J Lab Comp Radiopharm 1999;42:653-61.
26. 131I]meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 2004;1:50-7.
27. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G. Br J Cancer 1991;64:293-5.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:61-102.
30. Olive PL, Banath JP, Durand RE. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 1990;82:779-83.
31. 125I-meta- iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999;35:1227-34.
32. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/ cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Int J Paediatr 2004;93:6-11.
33. Keshelava N, Groshen S, Reynolds P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000;45:1-8.
34. Del Bino G, Skierski JS, Darzynkiewicz Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res 1990;50:5746-50.
35. 2 arrest and the cytotoxicity of campothecin in human carcinoma cells. Cancer Res 1996;56:4430-7.
36. 2 phase of Chinese hamster ovary cells. Nucleic Acids Res 2004;32:2677-84.
37. Golding SE, Rosenberg E, Khalil A, McEwen A, Holmes M, Neill S, et al. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem 2004;279:15402-10.
38. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:191-5.